Human Reproductive Technologies Market - Size, Share, Outlook, and Opportunity Analysis, 2019

Human reproductive technologies assist parents who are having troubles in pregnancies, and infertility issues. These technologies include Assisted Reproductive Technology (ART), prognostics, contraception, and same-sex procreation. ART aids in the treatment of low fertility or infertility using artificial insemination, artificial reproduction, cloning, cytoplasmic transfer, fertility medication, hormone treatment, and others.

Restraints of the Global Human Reproductive Technologies Market

Major factors hampering the growth of the human reproductive technologies market during the forecast period constitutes of limited insurance coverage for ART, and low adoption of emergency human reproductive technologies in emerging economies.

Key features of the study:

This report provides in-depth analysis of the global human reproductive technologies market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global human reproductive technologies market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Abbott Laboratories, Evofem Biosciences, Inc., Actavis Generics (Teva Pharmaceutical Industries Ltd.), Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Uniprix, Gavis Pharmaceuticals (Lupin Limited), Sandoz International GmbH, Aurobindo Pharma Limited, HRA Pharma, SA, Mankind Pharma, Cryos USA, Merck & Co, Bayer HealthCare AG, Church & Dwight, Co. Inc., Allergan, Pfizer, Inc., Agile Therapeutics Inc., BioSante Pharmaceuticals Inc., Mayer Laboratories, Inc., Pantarhei Bioscience B.V., Cook Medical, Inc., Ferring Pharmaceuticals, Johnson & Johnson, Daré Bioscience, Inc., and Merck Serono.
Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global human reproductive technologies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

Global Human Reproductive Technologies Market, By Technology: